Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel C Adelman

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Digestive Diseases and Sciences|September 28, 2011
Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trialsMatthew Siegel, Mitchell E Garber, Andrew G Spencer, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 14, 2021
Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergyCaroline Nilsson, Amy M Scurlock, Evan S Dellon, et al.
Cellular and Molecular Gastroenterology and Hepatology|May 17, 2017
A B-Cell Gene Signature Correlates With the Extent of Gluten-Induced Intestinal Injury in Celiac DiseaseMitchell E Garber, Alok Saldanha, Joel S Parker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2011
Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancerLee M Krug, Jeffrey Crawford, David S Ettinger, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 28, 2025
Barriers and Solutions to Optimal Food Allergy Prevention, Diagnostic, and Management StrategiesSteve A Tilles, Daniel C Adelman, Matthew Greenhawt, et al.
Allergy|July 28, 2021
Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergyMontserrat Fernandez-Rivas, Andrea Vereda, Brian P Vickery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2010
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedulesRanjana H Advani, Herbert I Hurwitz, Michael S Gordon, et al.
The Journal of Allergy and Clinical Immunology|January 13, 2022
Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food AllergyR Sharon Chinthrajah, Stacie M Jones, Edwin H Kim, et al.
Allergy|March 10, 2022
Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responsesVeronique Bajzik, Hannah A DeBerg, Nahir Garabatos, et al.
Circulation|August 27, 2003
Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term resultsDean J Kereiakes, Arthur M Szyniszewski, Dennis Wahr, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Digestive Diseases and Sciences|September 28, 2011
Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trialsMatthew Siegel, Mitchell E Garber, Andrew G Spencer, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 14, 2021
Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergyCaroline Nilsson, Amy M Scurlock, Evan S Dellon, et al.
Cellular and Molecular Gastroenterology and Hepatology|May 17, 2017
A B-Cell Gene Signature Correlates With the Extent of Gluten-Induced Intestinal Injury in Celiac DiseaseMitchell E Garber, Alok Saldanha, Joel S Parker, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2011
Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancerLee M Krug, Jeffrey Crawford, David S Ettinger, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 28, 2025
Barriers and Solutions to Optimal Food Allergy Prevention, Diagnostic, and Management StrategiesSteve A Tilles, Daniel C Adelman, Matthew Greenhawt, et al.
Allergy|July 28, 2021
Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergyMontserrat Fernandez-Rivas, Andrea Vereda, Brian P Vickery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2010
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedulesRanjana H Advani, Herbert I Hurwitz, Michael S Gordon, et al.
The Journal of Allergy and Clinical Immunology|January 13, 2022
Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food AllergyR Sharon Chinthrajah, Stacie M Jones, Edwin H Kim, et al.
Allergy|March 10, 2022
Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responsesVeronique Bajzik, Hannah A DeBerg, Nahir Garabatos, et al.
Circulation|August 27, 2003
Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term resultsDean J Kereiakes, Arthur M Szyniszewski, Dennis Wahr, et al.
Pageof 3